Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer. Dana-Farber’s Ana Garrido-Castro, MD, presented findings at #ASCO24. Video published 6/7/2024
FAQs About GiveTaxFree Answered! PART III
Share
givetaxfree.org
SACI-IO HR+: Ana Garrido-Castro, MD | Dana-Farber Cancer Institute [Video]
Categories
Welcome to GIVETAXFREE.ORG - NON-PROFIT Crowdfunding Site
Share
givetaxfree.org
![Behind the Breakthroughs | Closing the Gap: Equity in Clinical Trials, Research and Patient Care [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_349877_0_0jpg.jpg)
![Living Well Webinar Returning to Work [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_350042_0_0jpg.jpg)
![Boosting HPV Vaccination: Expert Tips from the Frontline [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/06/mp_348134_0_0jpg.jpg)
![Stem Cell Expert Shares Tips to Hack Cancer [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/06/mp_343967_0_0jpg.jpg)
